Clarus raises $660M for new life sciences fund

Clarus Ventures has raised $660 million for its second life sciences fund. Principals with the fund say they've invested 90 percent of the first biotech fund of $500 million, which was raised in 2005. And the life sciences field has remained hot for investors. The National Venture Capital Association, PricewaterhouseCoopers and Thomson Financial concluded that a third of all venture money went to biotech and medical device makers in the last quarter of 2007. 

"We have effectively completed the deployment of our first fund and built a diversified portfolio of exciting companies," said Robert Liptak, a Clarus Ventures Managing Director. "These include companies with...breakthrough products and technologies such as Aerovance, Centaurus, CoMentis, ESBATech, Pearl, ProActa, SarCode, Taligen, and Variation."

- read the release for more
- check out the report from The Boston Globe

Related Articles:
Clarus closes $500M fund. Report
Billion-dollar baby: Biotech still on a roll with VC funds. Report
The top 20 VC deals of 2007. Report
Biotech, emerging markets are big VC targets. Report

Suggested Articles

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.